ASX Giants Face Scrutiny: Can WiseTech, Cochlear, and CSL Bounce Back in 2026?
The Australian stock market has seen some of its most prominent players experience significant turbulence over the past year. WiseTech Global Ltd (ASX: WTC), Cochlear Ltd (ASX: COH), and CSL Ltd (ASX: CSL) – all key components of the S&P/ASX 200 Index (ASX: XJO) – have endured a challenging period, making them the worst-performing shares on the index over the last 12 months. This raises a crucial question for investors: is a rebound on the horizon for these beaten-down stocks, or is further decline anticipated in 2026?
WiseTech Global Ltd (ASX: WTC): A Tech Stock Under Pressure
WiseTech Global, a leader in logistics execution software, has been particularly hard hit. At the time of writing, its shares have experienced a substantial decline, down around 40% year-to-date and a staggering 61% compared to 12 months ago. This steep drop has been attributed to a broader tech sector sell-off and a general investor rotation towards more defensive assets amidst global economic uncertainty.
However, there are strong indications that WiseTech possesses significant potential for a resurgence. Its flagship CargoWise platform is deeply integrated into the global logistics industry, creating a formidable competitive moat and making it difficult for competitors to dislodge. Furthermore, CEO Zubin Appoo has highlighted the transformative impact of artificial intelligence, which is not only enhancing the company’s existing advantages but also unlocking new efficiencies and delivering increased value to its clientele.
The upcoming release of its FY26 financial results in August is anticipated to be a pivotal moment. A strong performance that meets or exceeds expectations could significantly shift investor sentiment, potentially triggering a rapid re-evaluation and a surge in buying activity.
Market analysts appear to be optimistic about WiseTech’s prospects. Broker consensus leans heavily towards a “buy” recommendation, with projections suggesting a potential upside of 87% over the next 12 months, targeting an average price of $76.43.
Cochlear Ltd (ASX: COH): Navigating Healthcare Headwinds
Cochlear, a global leader in implantable hearing solutions, has also faced considerable headwinds. Shares have seen a further decline, trading down approximately 3% on the day and now sitting 62% lower year-to-date and 64% below their value from 12 months prior.
The significant downturn in April was triggered by a substantial downgrade to the company’s FY26 earnings guidance. This revision was attributed to weakening conditions in developed markets and softer consumer demand. This downgrade was particularly impactful, representing one of the most severe in the company’s history as a listed entity, and followed a weaker-than-expected half-year result reported in February.
Beyond its specific challenges, Cochlear has also been affected by a broader market rotation away from ASX healthcare stocks. Factors such as global volatility, a weakening US dollar, increased US tariffs, and rising labour costs have prompted investors to divest their holdings in the sector.
Despite these setbacks, the sharp sell-off suggests that Cochlear shares may now be trading significantly below their intrinsic value. While short-term earnings have been impacted, the company remains a dominant global player with a robust long-term outlook. Forecasts indicate a recovery in earnings over the next one to two years.
While the immediate trajectory for 2026 remains uncertain, brokers are confident in the stock’s ability to rebound within the next 12 months. They generally rate Cochlear shares as a “buy,” with an average price target suggesting a potential upside of 102% to $196.95.
CSL Ltd (ASX: CSL): A Biotech Giant’s Temporary Setback?
CSL, a global biotherapeutics leader, has also experienced a difficult period, with its shares trading down around 2% on the day. The stock is currently down 46% year-to-date and 63% lower than its value 12 months ago.
The company’s most significant one-day decline occurred in early May, following a downward revision of its FY26 outlook. This revision, made after an interim CEO’s 90-day review, cited challenges including weakness in China’s albumin pricing, inventory normalisation within the US immunoglobulin market, and various operational factors impacting profitability. These issues have reinforced investor concerns about ongoing pressure on earnings momentum.
CSL has also been caught in the broader market trend of investors moving away from healthcare-related stocks.
While CSL has acknowledged that its growth initiatives are progressing, it has also noted that the financial benefits will take longer to materialise than initially anticipated. This suggests that a significant rebound may not be imminent.
The prevailing sentiment is that while a recovery is expected eventually, it may not occur within 2026. Indeed, further downside could precede any sustained upward movement. The majority of brokers currently maintain a “hold” rating on CSL shares, though the average price target suggests a potential upside of 66%, reaching $153.62.
Key Considerations for Investors
- WiseTech Global (WTC): Strong embedded platform, AI integration, and positive broker sentiment point to potential rebound. FY26 results are a key catalyst.
- Cochlear Ltd (COH): Significant sell-off may have oversold the stock. Long-term fundamentals remain intact, with analyst confidence in a near-term recovery.
- CSL Ltd (CSL): Facing short-to-medium term headwinds, with a longer recovery timeline expected. Potential for upside exists, but likely not in the immediate future.
The coming months will be critical for these ASX heavyweights as they navigate market sentiment, operational challenges, and the broader economic landscape. Investors will be closely watching their performance and strategic developments to determine if these beaten-down stocks can reclaim their former glory.
